Reviewer's report

**Title:** Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study

**Version:** 1  **Date:** 4 September 2013

**Reviewer:** Tim Clarner

**Reviewer's report:**

In the work by Balak and colleagues, the authors investigated the prevalence of cutaneous adverse effects in multiple sclerosis patients being treated with disease modifying therapy. Furthermore, they assessed the impact of cutaneous adverse events on quality of life in these patients. The manuscript is well written, the methods used are appropriate and all relevant methodical information is included. The data interpretation is comprehensible and limitations of the work are clearly stated and discussed. The manuscript meets the scope of BMC Neurology to publish articles dealing with management of neurological disorders.

I consider the manuscript relevant to physicians working with MS patients or scientists working on related research fields.

The manuscript is acceptable for publication in its current form and needs no further improvement.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

I declare that I have no competing interests